Gemmer Asset Management LLC Grows Position in Johnson & Johnson (NYSE:JNJ)

Gemmer Asset Management LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 11.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 9,298 shares of the company’s stock after purchasing an additional 923 shares during the quarter. Gemmer Asset Management LLC’s holdings in Johnson & Johnson were worth $1,345,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Cove Private Wealth LLC lifted its stake in shares of Johnson & Johnson by 14.2% in the 4th quarter. Cove Private Wealth LLC now owns 9,692 shares of the company’s stock valued at $1,402,000 after purchasing an additional 1,206 shares during the period. Zhang Financial LLC increased its position in Johnson & Johnson by 16.4% during the 4th quarter. Zhang Financial LLC now owns 12,380 shares of the company’s stock valued at $1,790,000 after buying an additional 1,740 shares in the last quarter. Guinness Atkinson Asset Management Inc increased its position in Johnson & Johnson by 23.2% during the 4th quarter. Guinness Atkinson Asset Management Inc now owns 7,316 shares of the company’s stock valued at $1,058,000 after buying an additional 1,378 shares in the last quarter. Guinness Asset Management LTD increased its position in Johnson & Johnson by 5.2% during the 4th quarter. Guinness Asset Management LTD now owns 1,393,460 shares of the company’s stock valued at $201,433,000 after buying an additional 69,338 shares in the last quarter. Finally, AMI Investment Management Inc. increased its position in Johnson & Johnson by 6.7% during the 4th quarter. AMI Investment Management Inc. now owns 25,492 shares of the company’s stock valued at $3,687,000 after buying an additional 1,607 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on JNJ. Wells Fargo & Company raised their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Guggenheim lifted their target price on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Finally, Wolfe Research began coverage on Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $173.27.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $145.39 on Thursday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The firm has a market capitalization of $350.04 billion, a P/E ratio of 21.04, a PEG ratio of 2.50 and a beta of 0.51. The business has a fifty day moving average of $148.26 and a 200 day moving average of $156.12.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22,438,500 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.29 earnings per share. As a group, sell-side analysts anticipate that Johnson & Johnson will post 9.95 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.41%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.